A look under the hood of atai's tech platform
Technologies & Trends Shaping the Future of Psychedelic Medicine
A review of "Can pragmatic trials help safeguard the development of psychedelic medicine?"
Welcome to "Late-Stage" DSM categorization of mental disorders
Hello! On the occasion of my recent appearance on the Business Trip Podcast, where I spoke with Greg Kubin of the Psychedelic Medicine Syndicate, I wan…
Hi, Thanks for checking in. In case this is your first time here, The Trip Report is a newsletter created by, me, Zach Haigney. It is an attempt to exp…
Dear Readers, It is time to think about the next chapter of The Trip Report. I have decided to take a hiatus from the 2-3 posts/week schedule that we'v…
Psychedelic News Roundup In Partnership with Lucid News Policy Can Psychedelics Help Save America? A Healthcare and bioethics group at Harvard Law scho…
There’s a tactic agreement that safety and efficacy are not going to be the barrier to rolling out psychedelic medicine— but rather, delivery will prov…
Field Trip IPO On Tuesday, Field Trip Psychedelics became the third publicly traded psychedelic company with at least a $100 million valuation behind M…
Jaguar makes one of the two FDA approved Botanical Drugs
On November 3rd Oregon voters will have the chance to vote for Measure 109, a state-regulated psilocybin therapy framework. It is the first state-level…